Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.
ClearNote Health targets early pancreatic cancer detection with multi-analyte blood test data
ClearNote Health will present Avantect pancreatic cancer test validation data at ASCO 2026. Find out what it could mean for early detection.
Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval
Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.
Why Apotex’s Apo-Semaglutide approval could reshape Canada’s diabetes drug market
Canada has generic Ozempic momentum. Apotex’s approval turns GLP-1 access into a pricing and supply-chain test.
Can Lupin Limited gain ground in cardiometabolic generics with United States dapagliflozin launch?
Lupin Limited has launched generic dapagliflozin in the United States. Read what it means for Farxiga, pricing pressure, and market access.
Novo Nordisk’s Awiqli approval could change how basal insulin is used in type 2 diabetes
Novo Nordisk’s Awiqli wins FDA approval as the first once-weekly basal insulin. Read what this could change for type 2 diabetes care.
What the Hims & Hers Health, Inc. and Novo Nordisk collaboration reveals about the future of obesity drug commercialization
Explore how Hims & Hers and Novo Nordisk are expanding GLP-1 access and what it means for obesity care, pricing, and regulation.
What Insulet’s EVOLUTION 2 data means for automated insulin delivery in type 2 diabetes
Insulet’s EVOLUTION 2 study shows 68% TIR with no boluses in type 2 diabetes. Analysis of what the FCL data means before the EVOLVE pivotal trial.
Hua Medicine’s dorzagliatin wins Hong Kong approval: what the glucokinase activator milestone means for diabetes treatment
Hua Medicine’s dorzagliatin wins Hong Kong approval for Type 2 diabetes. Discover what this glucokinase activator milestone means for global diabetes treatment.
Sciwind Biosciences and Pfizer China bet on ecnoglutide as China’s GLP-1 market enters its most competitive phase
Sciwind Biosciences partners with Pfizer China on ecnoglutide. Explore what this GLP-1 deal changes for obesity, diabetes, and China’s drug market.